Source:http://linkedlifedata.com/resource/pubmed/id/21407961
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2011-3-16
|
pubmed:abstractText |
In a double-blind, prospective study, 40 patients diagnosed with DSM-IV generalized anxiety disorder and stabilized on alprazolam therapy were randomized to receive the same dose of either conventional or sustained-released alprazolam for two weeks, followed by the other formulation of alprazolam in an identical dose for a further two weeks. Conventional alprazolam was administered thrice daily while the sustained-release formulation was administered once-daily, in the morning. Thirty four patients completed the study. Recruitment into the study was associated with a significant decrease in all measures of illness severity; however, no efficacy differences between the two forms of alprazolam were observed. Adverse effects, specifically insomnia, were reported more with the sustained-release formulation. It is concluded that once-daily sustained-release alprazolam is as effective as the conventional form of the drug, and may be preferable because of a wide range of advantages; in this study, the higher incidence of adverse effects with the sustained-release drug was probably an artefact of the experimental design, which fostered a (nighttime) state of partial drug withdrawal.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21407961-3774930,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21407961-7806686,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21407961-8145176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21407961-8328566,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21407961-9184613,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21407961-9850204
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:status |
PubMed-not-MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0019-5545
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
302-7
|
pubmed:dateRevised |
2011-7-27
|
pubmed:year |
2000
|
pubmed:articleTitle |
A double-blind, controlled evaluation of the efficacy and adverse effect profile of sustained-release alprazolam.
|
pubmed:affiliation |
CHITTARANJAN ANDRADE, MD., Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029.
|
pubmed:publicationType |
Journal Article
|